Landmark study validates accuracy of at-home hormone monitoring
A landmark clinical study published in *Reproductive BioMedicine Online* has validated the accuracy of at-home quantitative multi-hormone monitoring, marking a significant milestone in decentralized reproductive care. The 18-month, STARD-compliant study, led by Dr. Thomas P. Bouchard and involving 121 ovulatory cycles and 890 transvaginal ultrasound scans, demonstrated that the Mira at-home hormone monitor achieved 96% agreement with ultrasound-confirmed ovulation.
The study, which evaluated the Mira monitor's performance in measuring luteinizing hormone (LH), estrogen (E13G), progesterone (PDG), and follicle-stimulating hormone (FSH), found that ovulation occurred within ±1 day of the Mira LH peak in 96% of cycles. This high correlation aligns with the Mira monitor's ability to provide precise hormone data, supporting its use as a reliable tool for at-home ovulation prediction and confirmation.
Key findings from the study include: - High Precision with Ultrasound Gold Standard: Ovulation was confirmed within ±1 day of the Mira LH peak in 96% of cycles, with an intraclass correlation coefficient of 0.971. - Strong Correlation with Blood Serum Levels: First-morning urine hormone profiles closely mirrored serum blood draws, with strong correlations for LH (R² = 0.92), PDG (R² = 0.75), E13G (R² = 0.73), and FSH (R² = 0.61). - Biological Variability Beyond Calendar Estimates: Even among women with regular periods, 11% of cycles were anovulatory, and 12.4% of ovulations occurred while LH levels were still rising, highlighting the importance of continuous multi-hormone tracking. - Earlier Fertile Window Identification: Urinary estrogen (E13G) signals rose approximately 5 to 6 days prior to ovulation, providing earlier insight into the fertile window compared to LH tracking alone.
Dr. Bouchard, who led the study, noted, "For over two decades, at-home fertility tracking was based on qualitative indicators without providing quantitative hormone values. By evaluating quantitative four-hormone tracking against 890 ultrasound scans with a blinded, STARD-compliant protocol, this study establishes rigorous clinical and research benchmarks for at-home ovulation prediction and confirmation."
Sylvia Kang, Founder and CEO of Mira, stated, "Women deserve precise biological data about their reproductive health without needing constant clinic visits and serial blood draws. This study validates that quantitative at-home testing delivers clinic-grade hormonal visibility, marking a transformative step forward for decentralized healthcare, fertility care, and personalized hormone monitoring."
The study's findings are expected to broaden clinical adoption of at-home hormone tracking, offering a reliable, non-invasive diagnostic tool that can reduce the need for repeated clinic visits. Mira's technology, which measures exact numerical hormone concentrations, is designed to empower women with highly accurate, clinically-validated data to navigate fertility, menopause, and overall hormonal health with confidence.
Dr. Bouchard concluded, "This study not only updates 25-year-old industry benchmarks but also paves the way for more personalized and convenient reproductive healthcare solutions."
The results of this study, published in *Reproductive BioMedicine Online*, underscore the potential of at-home hormone monitoring to transform reproductive healthcare and decentralized medicine, providing women with the tools they need to take charge of their reproductive health.